Association of sodium-glucose cotransporter 2 inhibitor use with risk of osteoporotic fracture among older women: A nationwide, population-based cohort study
Main finding · Vertebral fractureResult — go to the resultHazard ratio 1.40 95 % CI 1.00–1.96Authors' conclusion
SGLT2i use showed an increased risk of vertebral fracture than non-SGLT2i use in elderly women. Although further validation is required, SGLT2i should be cautiously prescribed in older women due to the potential association with fracture risk.
Study context
- Population
- Women ≥65 years with T2D newly prescribed antidiabetic medications (ADMs) other than GLP-1 RA and TZD, with comprehensive health check-up data; National Health Insurance Service of Korea (2013–2020)matched 1:2
- Participants
- 1,333 vs 2,626
- Exposure
- SGLT2i use vs non-SGLT2i use
- SGLT2i usersn = 1,333
- Non-SGLT2i usersn = 2,626reference
- Outcome
- Vertebral fracture
- Follow-up
- follow-up period
Methodological detailsnationwide, propensity score matched 1:2
- Nationwide
- Propensity score matched 1:2
Main finding
As reported in the abstract
Hazard ratio
1.40
95 % CI 1.00–1.96
P = 0.049
By group
SGLT2i users
19.2 per 1,000 person-years
Non-SGLT2i users
13.8 per 1,000 person-years
SGLT2i usersvs Non-SGLT2i users
HR 1.40 (95 % CI 1.00–1.96); P = 0.049
Observational data: associations, not effects.
Further findings
- No significant difference in other types of fracture
Original publication
Association of sodium-glucose cotransporter 2 inhibitor use with risk of osteoporotic fracture among older women: A nationwide, population-based cohort study. Diabetes Res Clin Pract. Published 18 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →